Treatable Neonatal Molybdenum Cofactor Deficiency: Rapid Demise Despite Rapid Biochemical Diagnosis
Open Access
- 11 January 2026
- journal article
- Published by Wiley in JIMD Reports
- Vol. 67 (1)
Abstract
Molybdenum cofactor deficiency (MoCD) is an inborn error of metabolism included in the differential for refractory neonatal seizures. The prognosis is guarded, with a median reported age of death between 2.4 and 3.0 years. Mortality is primarily due to seizures and lower respiratory tract infections. MoCD has a distinct biochemical profile, characterized by elevated urinary S ‐sulfocysteine, xanthine, and hypoxanthine, and low or undetectable serum and urine uric acid levels. A disease‐altering treatment is available for MoCD Type A; however, due to the rarity of the condition, its natural history remains poorly understood. We present a patient with neonatal‐onset refractory seizures, whose biochemical testing, performed within 24 h of specimen receipt in the laboratory, revealed a pattern consistent with MoCD. Before the genetics team could disclose the preliminary diagnosis, the patient demised, without evidence of worsening seizures or respiratory infection. Results of genome sequencing, guided by biochemical findings, identified double homozygous pathogenic variants in MOCS1 (associated with MoCD Type A). Although the biochemical genetics laboratory's protocol for analyzing and reporting S ‐sulfocysteine levels within 48 h enabled a rapid preliminary diagnosis, the patient's condition deteriorated too quickly to initiate disease‐altering treatment, progressing more rapidly than described in the literature. We discuss potential hypotheses for his rapid decline and the broader implications for the field of biochemical genetics.Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort studyThe Lancet, 2015
- IKs Gain‐ and Loss‐of‐Function in Early‐Onset Lone Atrial FibrillationJournal of Cardiovascular Electrophysiology, 2015
- Molybdenum cofactor deficiency: Mutations in GPHN, MOCS1, and MOCS2Human Mutation, 2010
- Successful Treatment of Molybdenum Cofactor Deficiency Type A With cPMPPediatrics, 2010
- Biophysical Properties of 9 KCNQ1 Mutations Associated With Long-QT SyndromeCirculation: Arrhythmia and Electrophysiology, 2009
- Revisting wilson and Jungner in the genomic age: a review of screening criteria over the past 40 yearsBulletin of the World Health Organization, 2008
- Identification of the Missing Component in the Mitochondrial Benzamidoxime Prodrug-converting System as a Novel Molybdenum EnzymeJournal of Biological Chemistry, 2006
- Implementing tandem mass spectrometry as a routine tool for characterizing the complete purine and pyrimidine metabolic profile in urine samplesJournal of Mass Spectrometry, 2006
- GeneReviews®1993
- [Principles and practice of mass screening for disease].1968